Study assessing changes in LD pharmacokinetics when OPCs were combined with a fixed-dose combination of LD/dopa decarboxylase inhibitor (DCI) in order to implement a rational prescribing design when OPCs are used

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levodopa (Primary) ; Opicapone (Primary)
Indications Parkinson's disease
Focus Pharmacokinetics

Most Recent Events

05 Nov 2022 New trial record
18 Sep 2022 Results presented at the 26th International Congress of Parkinson's Disease and Movement Disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight